Skip to content

An Evaluation of a Antimicrobial Stewardship Recommendation Bundle for Staphylococcus Aureus Bloodstream Infections

An Evaluation of a Antimicrobial Stewardship Recommendation Bundle for Staphylococcus Aureus Bloodstream Infections

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06211829
Enrollment
77
Registered
2024-01-18
Start date
2022-05-18
Completion date
2025-07-14
Last updated
2025-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial Infections

Brief summary

In July 2020, a bundle (Appendix C) was implemented at Methodist Dallas Medical Center where all patients with SAB were reviewed by the antimicrobial stewardship pharmacist (Monday - Friday from 0700 to 1500), a note outlining optimal interventions was written in the electronic medical record (EMR), and the recommendations were communicated to the primary team via secure messaging or telephone

Detailed description

Evaluation of the Staphylococcus aureus bloodstream infection(SAB)bundle recommendations will allow for determination of whether this intervention is impactful and warrants the resources currently devoted to it.

Interventions

None listed

Sponsors

Methodist Health System
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years

Inclusion criteria

* 18 years of age SAB during hospital admission

Exclusion criteria

* Patients with a history of a prior SAB during the study period (only first occurrence included) * Blood culture collected within 48hours of patient expiring or transitioning to hospice * Patients discharged or left before culture results were available * Patients transferred from an outside hospital

Design outcomes

Primary

MeasureTime frameDescription
number of Staphylococcus Aureus blood stream infections (SAB)12 weeksNumber of SAB occurring

Secondary

MeasureTime frameDescription
Number of In-hospital mortality12 weeksNumber of In-hospital mortality
number of times of bacteremia12 weekstime of bacteremia
number of days of stay12 weeksduration of hospital stay
number of times of readmission12 weeksNumber time of readmission
number of infection12 weeksNumber of times the infection is occurring

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026